. A nurse is preparing to administer filgrastim 5 mcg/kg/day subcutaneous to a client who weighs 143 lb. How many mcg should the nurse administer per day? (Round the answer to the nearest whole number. Use a leading zero if it applies. Do not use a trailing zero.) _mcg

D) Oxycodone causes central nervous system depression: Oxycodone is an opioid analgesic that acts centrally on the central nervous system (CNS) to relieve pain. One of the most significant side effects of opioids like oxycodone is respiratory depression, which occurs due to the suppression of the CNS, particularly in the brainstem respiratory centers. The brainstem regulates respiratory rate and rhythm, and when opioids depress these centers, it can lead to decreased respiratory drive, resulting in a decrease in respiratory rate. A respiratory rate of 8/min is significantly below the normal range, indicating respiratory depression caused by oxycodone.

A) Oxycodone inhibits prostaglandin synthesis: Oxycodone does not directly inhibit prostaglandin synthesis. Prostaglandins are lipid compounds with various physiological effects, including inflammation and pain modulation. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, inhibit prostaglandin synthesis by blocking cyclooxygenase enzymes. However, oxycodone primarily acts on opioid receptors in the CNS to relieve pain, rather than through prostaglandin inhibition.

B) Oxycodone promotes vasodilation of cranial arteries: While opioids can cause peripheral vasodilation, particularly in large doses, the primary mechanism of action of oxycodone is not through the promotion of vasodilation of cranial arteries. Vasodilation may occur as a side effect of opioid use, but it is not the primary cause of respiratory depression associated with oxycodone.

C) Oxycodone blocks the sodium channel suspending nerve conduction: This statement describes the mechanism of action of local anesthetics, such as lidocaine, which block sodium channels to inhibit nerve conduction. However, oxycodone is not a sodium channel blocker. Its analgesic effects result from binding to opioid receptors in the CNS, particularly mu-opioid receptors, rather than blocking sodium channels. Therefore, this option is not the pathophysiology for the respiratory rate of 8/min observed in the client receiving oxycodone.

A) Ginkgo biloba: This is the correct answer. Ginkgo biloba is contraindicated for concurrent use with warfarin because it can increase the risk of bleeding due to its anticoagulant properties. It can potentiate the effects of warfarin, leading to an increased risk of bruising and bleeding complications.

B) Valerian: While valerian is an herbal supplement used for its sedative effects, it does not typically interact significantly with warfarin. However, caution should still be exercised when combining valerian with any medication due to its potential to cause drowsiness and enhance the effects of other central nervous system depressants.

C) Coenzyme Q10: Coenzyme Q10 is a dietary supplement that is generally well-tolerated and does not have significant interactions with warfarin. It is often used as an antioxidant and for various cardiovascular conditions.

D) Probiotics: Probiotics are beneficial bacteria that can aid in gut health but are unlikely to interact significantly with warfarin. However, it is essential to monitor for any potential changes in gastrointestinal function when starting probiotics concurrently with warfarin.